A Breakthrough in Avacopan Measurement: New LC-MS/MS Method Enables Precision Monitoring in Vasculitis Patient

Avacopan, a novel oral therapy for antineutrophil cytoplasmic antibody-associated vasculitis (ANCA-AAV), has changed treatment paradigms for this rare but serious disease. However, until now, a validated technique for measuring avacopan…

Continue Reading A Breakthrough in Avacopan Measurement: New LC-MS/MS Method Enables Precision Monitoring in Vasculitis Patient

The Impact of Pharmacy Benefit Managers and Most Favored Nation Policy on Biosimilar Adoption and Healthcare Costs

Editor's Note: This article is an opinion piece shared with Patient Worthy from our partner network. Opinion pieces may not reflect the views of Patient Worthy, its employees, or any…

Continue Reading The Impact of Pharmacy Benefit Managers and Most Favored Nation Policy on Biosimilar Adoption and Healthcare Costs

FDA Reviewing First-Ever Treatment for Barth Syndrome, Possibly Marking Major Milestone for Rare Disease Community

The U.S. Food and Drug Administration (FDA) is reviewing the first medication specifically developed for Barth syndrome, a rare and life-threatening genetic disorder. As reported by STAT, this medication could…

Continue Reading FDA Reviewing First-Ever Treatment for Barth Syndrome, Possibly Marking Major Milestone for Rare Disease Community

Sanofi’s SAR446523 Receives Orphan Drug Designation for Multiple Myeloma, Paving Way for Novel Treatment

Sanofi has announced a significant regulatory milestone for its investigational therapy SAR446523, a monoclonal antibody targeting GPRC5D, after the U.S. Food and Drug Administration (FDA) granted it orphan drug designation…

Continue Reading Sanofi’s SAR446523 Receives Orphan Drug Designation for Multiple Myeloma, Paving Way for Novel Treatment